1. Adam Z, Ševčík P, Vorlíček J, et al. Kostní nádorová choroba. Praha, Grada 2005, 296 s.
2. Adam Z, Sprláková-Puková A, Chaloupka R, et al. Atypická fraktura metatarsální kostni u pacienta s mnohočetným myelomem, který byl dlouhodobě léčeb bisfosfonáty. Vnitr Lek 2013;59:1022–1026.
3. Atula S, Powles T, Paterson A, McCloskey E. Extended safety profile of oral clodronate after long-term use in primary breast cancer patients. Drugs Safety 2003;26:661–671.
4. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580–8587.
5. Barrett-Lee P, Casbard A, Abraham J, et al. Oral ibandronic acid versusintravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. Lancet Oncol 2014;15:114–122.
6. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patientes with advanced multiple myeloma. N Engl J Med 1996;334:488–493.
7. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998;16:593–602.
8. Bergner R, Henrich DM, Hoffmann M, et al. Renal safety and pharmacokinetics of ibandronate in multiple myeloma patients with or without impaired renal function. J Clin Pharmacol 2007;47:942–950.
9. Bergner R, Henrich DM, Hoffmann M, etl al. Therapy of hypercalcemia with ibandronate in case of acute renal failure. Internist (Berl) 2006;47:293–296.
10. Body JJ. Reducing skeletal complications and bone pain with intravenouw ibandronate for metastatic bone disease. Eur J Cancer Suppl 2004;2:5–8.
11. Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003;14:1399–1405.
12. Body JJ, Lichinitser M, Tjulandin S, et al. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases. Ann Oncol 2007;18:1165–1171.
13. D’Arena G, Gobbi PG, Broglia C, et al. Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. Leuk Lymphoma 2011;52:771–775.
14. Damm DD, Jones DM. Bisphosphonate-related osteonecrosis of the jaws: A potential alternative to drug holidays. Gen Dent 2013;61:33–8.
15. de-Freitas NR, Lima LB, de-Moura MB, et al. Bisphosphonate treatment and dental implants: A systematic review. Med Oral Patol Oral Cir Bucal 2016;21:e644–e651.
16. Delmas PD, Charhon S, Chapuy E, et al. Long term effects of dichloromethylene diphosphate (C12MDP) on skeletal lesions in multiple myeloma. Metab Bone Dis Relat Res 1982;4:163–168.
17. Diel IJ, Weide R, Köppler H, et al. Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review. Support Care Cancer 2009;17:719–725.
18. Do WS, Park JK, Park MI, et al. Bisphosphonate-induced severe hypocalcemia – a case report. J Bone Metab 2012;19:139–145.
19. Durie BG, Katz, M, Crowley J. Osteonecrosis of the jaw and bisphosphonate. N Engl J Med 2005;353:99–102.
20. Epperla N, Pathak R. Hypocalcemia secondary to zoledronate therapy in a patient with low vitamin D level. WMJ 2015;114:163–166.
21. Favia G, Piattelli A, Sportelli P, Capodiferro S, Iezzi G. Osteonecrosis of the posterior mandible after implant insertion: a clinical and histological case report. Clin Implant Dent Relat Res 2011;13:58–63.
22. Ferlito S, Liardo C, Puzzo S. Bisphosponates and dental implants: a case report and a brief review of literature. Minerva Stomatol 2011;60:75–81.
23. Fung P, Bedogni G, Bedogni A, et al. Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study. Oral Dis 2017;23:477–483.
24. García-Sanz R, Oriol A, Moreno MJ, et al. Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial. Haematologica 2015;100:1207–1213.
25. Geng CJ, Liang Q, Zhong JH, et al. Ibandronate to treat skeletal-related events and bone pain in metastatic bone disease or multiple myeloma: a meta-analysis of randomised clinical trials. BMJ Open 2015;5:e007258.
26. Gimsing P, Carlson K, Turesson I, et al. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. Lancet Oncol 2010;11:973–982.
27. Grasko JM, Hermann RP, Vasikaran SD. Recurrent low-energy femoral shift fratures and osteonecrosis of the jaw in a case of multiple myeloma treated with bisphosphonates. J oral Maxillofac Surg 2009;67:645–649.
28. Hellstein JW, Adler RA, Edwards B, et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 2011;142:1243–51.
29. Henrich DM, Hoffmann M, Uppenkamp M, et al. Tolerability of dose escalation of ibandronate in patients with multiple myeloma and end-stage renal disease: a case series. Onkologie 2009;32:482–486.
30. Henrich D, Hoffmann M, Uppenkamp M, et al. Ibandronate for the treatment of hypercalcemia or nephrocalcinosis in patients with multiple myeloma and acute renal failure: Case reports. Acta Haematol 2006;116:165–172.
31. Chen F, Pu F. Safety of denosumab versus zoledronic acid in patients with bone metastases: a meta-analysis of randomized controlled trials. Oncol Res Treat 2016;39:453–459.
32. Jackson GH. Renal safety of ibandronate. Oncologist 2005;10:14–18.
33. Knauf W, Berger R, Kropff M, et al. Compare – result of a randomised study to assess the renal safety nad efficacy of ibandronate and zoledronate in multiple myeloma patients. Onkologie 2010;33:246.
34. Kreutle V, Blum C, Meier C, et al. Bisphosphonate induced hypocalcaemia - report of six cases and review of the literature. Swiss Med Wkly 2014;144:w13979.
35. Kwek EB, Koh JS, Howe TS. More on atypical fractures of the femoral diaphysis. N Engl J Med 2008;359:316–317.
36. Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007;25:2464–2472.
37. Lahtinen R, Laakso M, Palva I, et al. Randomised, placebo controlled multicentre trial of clodronate in multiple myeloma. Finnish leukemia Group. Lancer 1992;340:1049–1052.
38. Lee P, Seibel MJ. More on atypical fractures of the femoral diaphysis. N Engl J Med 2008;359:317–318.
39. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008;358:1304–1306.
40. Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis wollowing treatment with high dose pamidronate. J Am Soc Nephrol 2001;12:1164–1172.
41. Markowitz GS, Fine, PL, Stack FJ, et al. Toxic acute tubular necrosis following treatment with zolendronate (Zometa). Kidney Int 2003;64:281–289.
42. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115–1117.
43. McCloskey EV, MacLennan IC, Drayson MT, et al. A randomized trial of the effect of clodronate on skeletal morbitidy in multiple myeloma. MRC Working Party on Leukemia in Aduls. Brit J Haematol 1998;100:317–325.
44. Menssen HD, Sakalová A, Fontana A, et al. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 2002;20:2353–2359.
45. Mhaskar R, Redzepovic J, Wheatley K, et al. Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev 2012;(5):CD003188.
46. Montoya-Carralero JM, Parra-Mino P, Ramírez-Fernández P, et al. Dental implants in patients treated with oral bisphosphonates: a bibliographic review. Med Oral Patol Oral Cir Bucal 2010;15:e65–e69.
47. Morgan GJ, Davies FE, Gregory WM, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010;376:1989–1999.
48. Morgan GJ, Child JA, Gregory WM, et al. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncol 2011;12:743–752.
49. Morgan GJ, Davies FE, Gregory WM, et al. Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial. Blood 2012;119:5374–5383.
50. Musto P, Petrucci MT, Bringhen S, et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer 2008;113:1588–1595.
51. Noriega Aldave AP, Jaiswal S. Severe resistant hypocalcemia in multiple myeloma after zoledronic acid administration: a case report. J Med Case Rep 2014;8:353.
52. Pecherstorfer M, Rivkin S, Body JJ, et al. Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial. Clin Drug Investig 2006;26:315–322.
53. Puhaindran ME, Farooki A, Steensma MR, et al. Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates. J Bone Joint Surg Am 2011;93:1235–1242.
54. Raje N, Vadhan-Raj S, Willenbacher W, et al. Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial. Blood Cancer J 2016;6:e378.
55. Raje N, Terpos E, Willenbacher W, et al. An international, randomized, double blind trial comparing denosumab with zoledronic acid (ZA) for the treatment of bone disease in patients (Pts) with newly diagnosed multiple myeloma. Clin Lymphoma Myeloma Leuk 2017;17:e27–e28.
56. Rosella D, Papi P, Giardino R, et al. Medication-related osteonecrosis of the jaw: Clinical and practical guidelines. J Int Soc Prev Community Dent 2016;6:97–104.
57. Rosen LS, Gordon D, Tchekmedyian NS, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003;15:3150–3157.
58. Rosen LS, Gordon D, Kaminski M, et al. Zolendronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma. A phase III double blind comparative trial. Cancer J 2001;7:377–387.
59. Rugani P, Acham S, Kirnbauer B, et al. Stage-related treatment concept of medication-related osteonecrosis of the jaw-a case series. Clin Oral Investig 2015;19:1329–1338.
60. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphophonates; a review of 63 cases. J Oral Maxillofac Surg 2004;62:527–534.
61. Russell RG. Bisphosphonates: the first 40 years. Bone 2011;49:2–19.
62. Sauter M, Jülg B, Porubsky, S et al. Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: Mitochondrial toxicity as a pathogenetic koncept? Amer J Kidney Dis 2006;47:1075–1080.
63. Schneider JP Should bisphosphonates continued indefinitely. An unusual fracture in healthy woman ond long-term bisphosphonate. Geriatrics 2006; 61:31–33.
64. Snowden JA, Ahmedzai SH, Ashcroft J, et al. Guidelines for supportive care in multiple myeloma 2011. Br J Haematol 2011;154:76–103.
65. Tonogai I, Goto T, Hamada D, et al. Bilateral atypical femoral fractures in a patient with multiple myeloma treated with intravenous bisphosphonate therapy. Case Rep Orthop 2014;2014:452418.
66. Terpos E, Sezer O, Croucher PI, et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol. 2009;20:1303–1317.
67. Terpos E, Morgan G, Dimopoulos MA, et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol 2013;31:2347–2357.
68. Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 2008;93:2948–2952.
69. Walter C, Al-Nawas B, Wolff T, Schiegnitz E, Grötz KA. Dental implants in patients treated with antiresorptive medication - a systematic literature review. Int J Implant Dent 2016;2:9.
70. Waterman GN, Yellin O, Jamshidinia K, et al. Metatarsal stress fractures in patients with multiple myeloma treated with long-term bisphosphonates: a report of six cases. J Bone Joint Surg Am. 2011;93:e106.
71. Wernecke G, Namduri S, DiCarlo EF, et al. Case report of spontaneous nonspinal fracture in multiple myeloma pacient on long term pamidronate and zoledronic acid. HSS J 2008;4:123–127.
72. Witzig TE, Laumann KM, Lacy MQ, et al. A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. Leukemia 2013;27:220–225.